At a glance
- Originator Sanofi-Synthelabo
- Class Antiemetics
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Nausea and vomiting
Most Recent Events
- 23 May 1995 Discontinued-Preclinical for Emesis in France (Unknown route)